廣告
香港股市 已收市

  • 恒指

    17,284.54
    +83.27 (+0.48%)
     

  • 國指

    6,120.37
    +20.15 (+0.33%)
     

  • 上證綜指

    3,052.90
    +8.08 (+0.27%)
     

  • 道指

    38,460.92
    -42.77 (-0.11%)
     

  • 標普 500

    5,071.63
    +1.08 (+0.02%)
     

  • 納指

    15,712.75
    +16.11 (+0.10%)
     

  • Vix指數

    16.19
    +0.22 (+1.38%)
     

  • 富時100

    8,096.86
    +56.48 (+0.70%)
     

  • 紐約期油

    82.88
    +0.07 (+0.08%)
     

  • 金價

    2,339.40
    +1.00 (+0.04%)
     

  • 美元

    7.8294
    -0.0015 (-0.02%)
     

  • 人民幣

    0.9251
    +0.0004 (+0.04%)
     

  • 日圓

    0.0501
    -0.0001 (-0.30%)
     

  • 歐元

    8.3961
    +0.0204 (+0.24%)
     

  • Bitcoin

    64,098.88
    -2,297.01 (-3.46%)
     

  • CMC Crypto 200

    1,358.88
    -23.69 (-1.71%)
     

Amarin Touts Positive Data For Its Heart Disease Drug In Current/Former Smokers

Vandana Singh
·1 分鐘文章

  • Amarin Corporation plc (NASDAQ: AMRN) announced that new REDUCE-IT data show that Vascepa/Vazkepa (icosapent ethyl) significantly reduced cardiovascular (CV) events in patients with a history of smoking.

  • In this post hoc exploratory analysis, icosapent ethyl (IPE) treatment significantly reduced the risk of first and total primary composite events in current/former smokers by 23% and in former smokers by 29%, compared to the placebo.

  • Related: Amarin's New Vascepa Data Shows Significant Reduction In Heart Attack Subtypes.

  • IPE treatment reduced the incidence of CV events in current smokers by 23.8% and former smokers by 23.0% to levels observed in never smokers (25.7%) in the placebo group.

  • Compared with placebo, IPE use in combined current and former smokers was associated with significant reductions in first primary composite events and total primary composite events.

  • Overall, there were similar estimated rates of first occurrences of CV death, MI, stroke, coronary revascularization, or hospitalization for unstable angina in current smokers (23.8%) and former smokers (23.0%) assigned to IPE compared to the placebo (25.7%).

  • Price Action: AMRN shares closed lower by 2.31% at $1.27 on Friday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.